Instrument ManagerTM
Achieve your lab’s full potential with the industry’s most-used middleware platform for unrestricted connectivity, unlimited scalability, and centralized workflow management.
Total Allowable Error
Ensure patient results are consistently accurate and trustworthy by incorporating Total Allowable Error (TEa) with EP Evaluator®.
Challenges
Lab Quality Assurance with EP Evaluator
01.
Instrument validation is slow, complex, and prone to errors when done manually.
Solution: EP Evaluator runs 100+ study calculations at once and streamlines instrument comparisons for faster, more accurate verification
02.
Preparing compliant, professional reports for inspections takes excessive time and effort.
Solution: EP Evaluator delivers automated, concise, data-driven reports that are ready for audits and regulatory reviews.
03.
Meeting multiple regulatory and protocol requirements is challenging to manage.
Solution: EP Evaluator meets CLIA, CAP, The Joint Commission, and COFRAC standards while implementing eight major CLSI protocols
04.
Manual data entry and analysis wastes time and increases error risk.
Solution: EP Evaluator integrates with Instrument Manager for automated imports and offers 30+ statistical modules meeting CAP and CLIA ’88 standards.
Add EP Evaluator to your lab today!
TOTAL ERROR LIMITS
Total Allowable Error Table
| Analyte | Fluid | Method | Source | Target Value |
|---|---|---|---|---|
| 17-Hydroxyprogesterone | Serum | ±2.0 nmol/L or 20% if > 10.0 nmol/L | 5 RCPA | |
| 3-Methoxytyramine (3MT) | Urine | ±15 nmol/L or ±15% if > 100 nmol/L | 5 RCPA | |
| 4-hydroxy-3-methoxy-mandelate, (HMMA) | Urine | ±6 umol/L or 15% if > 40 umol/L | 5 RCPA | |
| 5HIAA | Urine | ±8 umol/L or 20% if > 40 umol/L | 5 RCPA | |
| a1-Antitrypsin (α1AT) | Serum | ±0.10 g/L or 20% if > 0.5 g/L | 5 RCPA, 6 API | |
| Acetaminophen (Paracetamol) | Serum | ±15% or 3 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Acetaminophen (Paracetamol) | Serum | ±15% or 2.5 µg/mL (greater) | 4 AAB | |
| Acetaminophen (Paracetamol) | Serum | ±3.0 mg/L or 10% if > 30.0 mg/L | 5 RCPA | |
| Activated Clotting Time (ACT) | WB | ±20% | 2 WSLH | |
| Adrenaline | Urine | ±30 nmol/L or 30% if > 100 nmol/L | 5 RCPA | |
| Adrenocorticotropic Hormone (ACTH) | Serum | ±2.0 pmol/L or 10% if > 20 pmol/L | 5 RCPA | |
| Alanine Aminotransferase (ALT) | Serum | ±15% or 6 U/L (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Alanine Aminotransferase (ALT) | Serum | ±20% | 4 AAB | |
| Alanine Aminotransferase (ALT) | Serum | ±5 U/L or 12% if > 40 U/L | 5 RCPA | |
| Albumin | Serum | ±8% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Albumin | Body Fluids | ±10% | 2 WSLH, 6 API | |
| Albumin | Serum | ±10% | 4 AAB | |
| Albumin | Serum, Body Fluids | ±2.0 g/L or 6% if > 33 g/L | 5 RCPA | |
| Albumin | CSF | ±0.02 g/L or 20% if > 0.1 g/L | 5 RCPA | |
| Albumin | Urine | ±4.0 mg/L or 20% if > 20.0 mg/L | 5 RCPA | |
| Alcohol (ETOH) | Serum | ±20% | 1 CLIA, 2 WSLH, 6 API | |
| Alcohol (ETOH) | Serum | ±25% | 4 AAB | |
| Alcohol (ETOH) | Serum | ±2.0 mmol/L or 10% if > 20 mmol/L | 5 RCPA | |
| Aldosterone | Serum | ±24 pmol/L or 15% if > 160 pmol/L | 5 RCPA | |
| Alkaline Phosphatase (ALP) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Alkaline Phosphatase (ALP) | Serum | ±30% | 4 AAB | |
| Alkaline Phosphatase (ALP) | Serum | ±15 U/L or 12% if > 125 U/L | 5 RCPA | |
| Alkaline Phosphatase (ALP) | Body Fluids | ±30% | 6 API | |
| Alpha 1 Antitrypsin | Serum | ±20% | 1 CLIA | |
| Alpha-fetoprotein (AFP) | Serum | ±20% | 1 CLIA, 2 WSLH, 6 API | |
| Alpha-fetoprotein (AFP) | Serum | ±2 kIU/L or 12% if > 17 kIU/L | 5 RCPA | |
| Aluminum | Serum | ±0.08 umol/L or 20% if > 0.40 umol/L | 5 RCPA | |
| Amikacin | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Amikacin | Serum | ±2 mg/L or 10% if > 19.9 mg/L | 5 RCPA | |
| Aminolaevulinic Acid (ALA) | Urine | ±8 umol/L or 25% if > 32 umol/L | 5 RCPA | |
| Amiodarone | Serum | ±0.1 mg/L or 10% if > 1.3 mg/L | 5 RCPA | |
| Amitriptyline | Serum | ±3.0 ug/L or 10% if > 28.0 ug/L | 5 RCPA | |
| Ammonia | Serum | ±5% or 10 µmol/L (greater) | 4 AAB | |
| Ammonia | Serum | ±5 umol/L or 10% if > 50 umol/L | 5 RCPA | |
| Amylase | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Amylase | Serum | ±30% | 4 AAB | |
| Amylase | Body Fluids, Urine | ±30% | 2 WSLH, 6 API | |
| Amylase | Serum | ±10 U/L or 10% if > 100 U/L | 5 RCPA | |
| Amylase | Body Fluids | ±20 U/L or 20% if > 100 U/L | 5 RCPA | |
| Androstenedione | Serum | ±1.5 nmol/L or 15% if > 10 nmol/L | 5 RCPA | |
| Angiotensin Converting Enzyme (ACE) | Serum | ±1.0 or 10% if > 10.0 U/L | 5 RCPA | |
| Antinuclear antibody (ANA) | Serum | ±2 dilutions or positive or negative | 1 CLIA | |
| Antistreptolysin O (ASO) | Serum | ±2 dilutions or positive or negative | 1 CLIA | |
| Antistreptolysin O (ASO) | Serum | ±3SD or ±25 IU/mL (greater) | 6 API | |
| Antithrombin, Functional (AT) | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
| Anti-CCP | Serum | ±3SD or ±5 U/mL (greater) | 6 API | |
| Anti HIV (Human Immunodeficiency virus) | Serum | Reactive (positive) or nonreactive (negative) | 1 CLIA | |
| Anti Xa | Plasma | ±25 ng/mL or 25% if > 100 ng/mL | 5 RCPA | |
| Apolipoprotein A1 | Serum | ±0.2 g/L or 10% if > 2.0 g/L | 5 RCPA | |
| Apolipoprotein B | Serum | ±0.2 g/L or 10% if > 2.0 g/L | 5 RCPA | |
| Arsenic, Total | Urine | ±50 nmol/L or 10% if > 500 nmol/L | 5 RCPA | |
| Arsenic, Total | WB | ±10 nmol/L or 10% if > 100 nmol/L | 5 RCPA | |
| Aspartate Aminotransferase (AST) | Serum | ±15% or 6 U/L (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Aspartate Aminotransferase (AST) | Serum | ±20% | 4 AAB | |
| Aspartate Aminotransferase (AST) | Serum | ±5 U/L or 12% if > 40 U/L | 5 RCPA | |
| Basophile, count | WB | ±3% or 30% if > 10% | 5 RCPA | |
| Beta-2 microglobulin (B2M) | Serum | ±0.2 mg/L or 10% if > 2.0 mg/L | 5 RCPA | |
| Beta Carotene | Serum | ±0.4 umol/L or 25% if > 2.0 umol/L | 5 RCPA | |
| Beta-Hydroxybutyrate | Serum | ±3SD or ±0.2 mmol/L (greater) | 6 API | |
| Bile Acids, Total | Serum | ±4 umol/L or 10% if > 40 umol/L | 5 RCPA | |
| Bilirubin, Direct or Conjugated (DBIL) | Serum | ±0.4 mg/dL or 20% (greater) | 2 WSLH, 3 CAP, 6 API | |
| Bilirubin, Direct or Conjugated (DBIL) | Serum | ±3 umol/L or 20% if > 15 umol/L | 5 RCPA | |
| Bilirubin, Neonatal (TBIL) | Serum | ±20% or 0.4 mg/dL (greater) | 4 AAB | |
| Bilirubin, Neonatal (TBIL) | Serum | ±8 umol/L or 10% if > 80 umol/L | 5 RCPA | |
| Bilirubin, Total | Serum | ±20% or 0.4 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Bilirubin, Total | Serum | ±3 umol/L or 12% if > 25 umol/L | 5 RCPA | |
| Bilirubin, Total | CSF | ±0.12 umol/L or 20% if > 0.6 umol/L | 5 RCPA | |
| Bilirubin, Total | Body Fluids | ±0.4 mg/dL or ±20% (greater) | 6 API | |
| B-natriuretic Peptide (BNP) | Serum | ±30% | 1 CLIA, 2 WSLH, 6 API | |
| B-natriuretic Peptide (BNP) | Serum | ±2 SD or 25% (greater) | 4 AAB | |
| B-natriuretic Peptide (BNP) | Serum | ±20 ng/L or 20% if > 100 ng/L | 5 RCPA | |
| B-natriuretic Peptide, Pro (proBNP) | Serum | ±30% | 2 WSLH, 6 API | |
| B-natriuretic Peptide, Pro (proBNP) | Serum | ±25% | 4 AAB | |
| B-natriuretic Peptide, Pro (proBNP) | Serum | ±25 ng/L or 20% if > 125 ng/L | 5 RCPA | |
| C Peptide | Serum | ±0.15 nmol/L or 12% if > 1.25 nmol/L | 5 RCPA | |
| C1 Inhibitor, Esterase (C1inh) | Serum | ±0.03 g/L or 15% if > ±0.2 g/L | 5 RCPA | |
| Cadmium | Urine, WB | ±1 mg/dL or 15% | 2 WSLH | |
| Cadmium | Urine, WB | ±3 nmol/L or 15% if > 20 nmol/L | 5 RCPA | |
| Caffeine | Serum | ±3 SD or 10% (greater) | 3 CAP, 6 API | |
| Calcitonin | Serum | ±2 ng/L or 10% if > 20 ng/L | 5 RCPA | |
| Calcium - Total | Serum | ±1.0 mg/dL | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Calcium - Total | Urine | ±10% or 1 mg/dL | 2 WSLH | |
| Calcium - Total | Serum | ±0.1 mmol/L or 4% if > 2.5 mmol/L | 5 RCPA | |
| Calcium - Total | Urine | ±0.2 mmol/L or 10% if > 2.0 mmol/L | 5 RCPA | |
| Calcium - Total | Body Fluids | ±1 mg/dL | 6 API | |
| Calcium, Ionized | Serum | ±0.13 mmol/L | 2 WSLH | |
| Calcium, Ionized | Serum | ±0.04 mmol/L or 4% if > 1.00 mmol/L | 5 RCPA | |
| Calcium, Ionized | Serum | ±3 SD or ±0.05 mmol/L (greater) | 6 API | |
| Cancer Antigen (CA) 125 | Serum | ±6 kU/L or 12% if > 50 kU/L | 5 RCPA | |
| Cancer Antigen (CA) 125 | Serum | ±20% | 6 API | |
| Cancer Antigen (CA) 15-3 | Serum | ±2 SD or 30% (greater) | 4 AAB | |
| Cancer Antigen (CA) 15-3 | Serum | ±3 kU/L or 10% if > 30 kU/L | 5 RCPA | |
| Cancer Antigen (CA) 19-9 | Serum | ±2 SD or 30% (greater) | 4 AAB | |
| Cancer Antigen (CA) 19-9 | Serum | ±6 kU/L or 15% if > 40 kU/L | 5 RCPA | |
| Cancer Antigen (CA) 19-9 | Body Fluids | ±12 kU/L or 30% if > 40 kU/L | 5 RCPA | |
| Cancer Antigen (CA) 27.29 | Serum | ±2 SD or 30% (greater) | 4 AAB | |
| Carbamazepine | Serum | ±20% or 1.0 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Carbamazepine | Serum | ±25% | 4 AAB | |
| Carbamazepine | Serum | ±0.5 mg/L or 10% if > 4.7 mg/L | 5 RCPA | |
| Carbamazepine, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Carcinoembryonic Antigen (CEA) | Serum | ±15% or 1 ng/mL (greater) | 1 CLIA, 2 WSLH, 6 API | |
| Carcinoembryonic Antigen (CEA) | Serum | ±1.2 ng/mL or 20% | 4 AAB | |
| Carcinoembryonic Antigen (CEA) | Serum | ±0.6 ug/L or 12% if > 5 ug/L | 5 RCPA | |
| Carcinoembryonic Antigen (CEA) | Body Fluids | ±1.2 ug/L or 24% if > 5.0 ug/L | 5 RCPA | |
| Carotenoids, Total | Serum | ±0.8 umol/L or 25% if > 4.0 umol/L | 5 RCPA | |
| CD3+ Alpha-beta% | WB | ±4.5% to 15% if > 30% | 5 RCPA | |
| CD3+% | WB | ±1.5% or 5% if > 30% | 5 RCPA | |
| CD3x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
| CD4x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
| CD3+/CD4+% | WB | ±3% or 7.5% if > 40% | 5 RCPA | |
| CD3+/CD8+% | WB | ±1.5% or 10% if > 15% | 5 RCPA | |
| CD3-CD16+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
| CD3-CD56+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
| CD3-CD16+56+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
| CD8x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
| CD19+% | WB | ±2% or 20% if > 10% | 5 RCPA | |
| CD19x109/L | WB | ±0.02x109/L or 20% if > 0.1x109/L | 5 RCPA | |
| CD34+, % | WB | ±0.05% or 25% if > 0.3% | 5 RCPA | |
| CD34+, Total | WB | ±5 uL or 25% if > 20 uL | 5 RCPA | |
| Ceruloplasmin | Serum | ±0.03 g/L or 15% if > 0.2 g/L | 5 RCPA | |
| Chloride | Serum | ±5% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Chloride | Urine | ±10% | 2 WSLH | |
| Chloride | Serum | ±3 mmol/L or 3% if > 100 mmol/L | 5 RCPA | |
| Chloride | Sweat | ±2.0 mmol/L or 5% if > 40 mmol/L | 5 RCPA | |
| Chloride | Urine | ±4.0 mmol/L or 10% if > 40 mmol/L | 5 RCPA | |
| Chloride | Body Fluids | ±2 SD or ±5% (greater) | 6 API | |
| Cholesterol, HDL | Serum | ±20% or 6 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP | |
| Cholesterol, HDL | Serum | ±30% | 4 AAB | |
| Cholesterol, HDL | Serum | ±0.1 mmol/L or 12% if > 0.8 mmol/L | 5 RCPA | |
| Cholesterol, LDL | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP | |
| Cholesterol, LDL | Serum | ±30% | 4 AAB | |
| Cholesterol, LDL | Serum | ±0.2 mmol/L or 10% if > 2.0 mmol/L | 5 RCPA | |
| Cholesterol, Total | Serum | ±10% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Cholesterol, Total | Body Fluids | ±10% | 2 WSLH | |
| Cholesterol, Total | Serum | ±0.3 mmol/L or 6% if > 5.0 mmol/L | 5 RCPA | |
| Cholesterol, Total | Body Fluids | ±0.3 mmol/L or 12% if > 2.5 mmol/L | 5 RCPA | |
| Cholinesterase | Serum | ±500 U/L or 10% if > 5000 U/L | 5 RCPA | |
| Chromium | Serum, Urine, WB | ±3 nmol/L or 12% if > 25 nmol/L | 5 RCPA | |
| Clozapine | Serum | ±12 ug/L or 12% if > 100 ug/L | 5 RCPA | |
| CO2, Carbon Dioxide (Bicarbonate) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| CO2, Carbon Dioxide (Bicarbonate) | Serum | ±2.0 mmol/L or 10% if > 20.0 mmol/L | 5 RCPA | |
| Cobalt | Plasma | ±1 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
| Cobalt | Urine | ±2 nmol/L or 10% if > 20 nmol/L | 5 RCPA | |
| Cobalt | WB | ±2 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
| Compatibility testing | Serum | 100% accuracy | 1 CLIA | |
| Complement C3 | Serum | ±15% | 1 CLIA, 6 API | |
| Complement C3 | Serum | ±0.10 g/L or 10% if > 1.0 g/L | 5 RCPA | |
| Complement C4 | Serum | ±20% or 5 mg/dL (greater) | 1 CLIA, 6 API | |
| Complement C4 | Serum | 0.02 g/L or 10% if > 0.2 g/L | 5 RCPA | |
| Conductivity | Sweat | ±2 mmol/L or 5% if > 50 mmol/L | 5 RCPA | |
| Copper | Serum | ±1.6 umol/L or 8% if > 20.0 umol/L | 5 RCPA | |
| Copper | Urine | ±0.05 umol/L or 10% if > 0.50 umol/L | 5 RCPA | |
| Cortisol | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Cortisol | Serum | ±25% | 4 AAB | |
| Cortisol | Serum | ±15 nmol/L or 15% if > 100 nmol/L | 5 RCPA | |
| Cortisol | Urine | ±30 nmol/L or 15% if > 200 nmol/L | 5 RCPA | |
| C-Reactive protein (CRP) | Serum | ±30% or 2 SD (greater) | 4 AAB | |
| C-Reactive protein (CRP) | Serum | ±0.8 mg/L or 20% if > 4.0 mg/L | 5 RCPA | |
| C-Reactive protein (CRP) | Serum | ±2 SD or ±0.3 mg/dL (greater) | 6 API | |
| C-Reactive protein (CRP), High Sensitivity | Serum | ±30% or 1 mg/L or 0.1 mg/dL (greater) | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| C-Reactive protein (CRP), High Sensitivity | Serum | ±0.6 mg/L or 20% if > 3.0 mg/L | 5 RCPA | |
| Creatine Kinase (CK) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Creatine Kinase (CK) | Serum | ±30% | 4 AAB | |
| Creatine Kinase (CK) | Serum | ±15 U/L or 12% if > 125 U/L | 5 RCPA | |
| Creatine Kinase Isoenzyme (CKMB) | Serum | ±25% or 3 ng/mL (greater) or MB elevated (presence or absence) | 1 CLIA, 2 WSLH, 6 API | |
| Creatine Kinase Isoenzyme (CKMB) | Serum | ±3 U/L or 3 ug/L or 20% if > 15 U/L or 15 ug/L | 5 RCPA | |
| Creatinine | Serum | ±10% or 0.2 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Creatinine | Body Fluids, Urine | ±17% or 0.3 mg/dL | 2 WSLH | |
| Creatinine | Serum | ±0.3 mg/dL or 15% (greater) | 4 AAB | |
| Creatinine | Serum, Urine | ±17% | 4 AAB | |
| Creatinine | Serum | ±8.0 umol/L or 8% if > 100 umol/L | 5 RCPA | |
| Creatinine | Body Fluids | ±16.0 umol/L or 16% if > 100 umol/L | 5 RCPA | |
| Creatinine | Urine | ±0.5 mmol/L or 10% if > 5.0 mmol/L | 5 RCPA | |
| Creatinine | Body Fluids | ±0.3 mg/dL or 15% (greater) | 6 API | |
| Creatinine | Urine | ±20% | 6 API | |
| Cyclosporine | Serum | ±10 ug/L or 10% if > 100 ug/L | 5 RCPA | |
| d-Dimer | Plasma | ±15% | 2 WSLH | |
| d-Dimer | Plasma | ±2 SD or 30% (greater) | 4 AAB | |
| d-Dimer | Plasma | automated DD | ±0.25 DD mg/L or 50% if > 0.5 DD mg/L | 5 RCPA |
| d-Dimer | Plasma | automated FEU | ±0.5 FEU mg/L or 50% if > 1.0 FEU mg/L | 5 RCPA |
| DHEA Sulfate | Serum | ±30% or 2 SD (greater) | 4 AAB | |
| DHEA Sulfate | Serum | ±1.2 umol/L or 12% if > 10 umol/L | 5 RCPA | |
| Digoxin | Serum | ±15% or 0.2 ng/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Digoxin | Serum | ±0.2 ng/dL or 20% (greater) | 4 AAB | |
| Digoxin | Serum | ±0.2 ug/L or 10% if > 1.6 ug/L | 5 RCPA | |
| Digoxin, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Dihydropyrimidine dehydrogenase (DPYD) Free | Urine | ±15 nmol/L or 15% if > 80 nmol/L | 5 RCPA | |
| Direct Thrombin Inhibitor, (DTI) | Plasma | ±25 ng/mL or 25% if >100 ng/mL | 5 RCPA | |
| Disopyramide | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Dopamine | Urine | ±0.2 umol/L or 10% if > 2.0 umol/L | 5 RCPA | |
| Eosinophils, count | WB | ±3% or 30% if > 10% | 5 RCPA | |
| Erythrocyte Sedimentation Rate (ESR) | WB | ±3.0 mm/hr or 30% if > 10 mm/hr | 5 RCPA | |
| Estradiol | Serum | ±30% | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| Estradiol (Oestradiol) | Serum | ±25 pmol/L or 25% if > 100 pmol/L | 5 RCPA | |
| Estriol, Unconjugated (Oestriol) | Serum | ±0.9 nmol/L or 15% if > 6.0 nmol/L | 5 RCPA | |
| Estriol, Unconjugated | Serum | ±2 SD or + 0.5ng/mL (greater) | 6 API | |
| Ethosuximide | Serum | ±20% | 3 CAP | |
| Ethylene Glycol | Serum | ±25% | 6 API | |
| Factor II, V, VII, IX, X, XI, XII | Plasma | ±3 IU/dL or 30% if > 10 IU/dL | 5 RCPA | |
| Factor VIII:C | Plasma | ±3% or 30% if > 10% | 5 RCPA | |
| Fecal Occult Blood (FOBT) | Stool | ±15 ng/mL or 15% if > 100 ng/mL | 5 RCPA | |
| Ferritin | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Ferritin | Serum | ±4.0 ug/L or 15% if 27.0 ug/L | 5 RCPA | |
| Fibrinogen | Plasma | ±20% | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| Fibrinogen | Plasma | ±0.2 g/L or 25% if > 1.0 g/L | 5 RCPA | |
| Fluconazole | Serum | ±2.0 mg/L or 10% if > 20 mg/L | 5 RCPA | |
| Flucytosine | Serum | ±10 mg/L or 10% if > 100 mg/L | 5 RCPA | |
| Folate | Serum | ±30% or 1 ng/mL (greater) | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| Folate | Serum | ±1.5 nmol/L or 25% if > 6.0 nmol/L | 5 RCPA | |
| Folate, RBC | WB | ±80 nmol/L or 20% if > 400 nmol/L | 5 RCPA | |
| Follicle Stimulating Hormone (FSH) | Serum | ±18% or 2 IU/L (greater) | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| Follicle Stimulating Hormone (FSH) | Serum | ±1.0 IU/L or 10% if > 10.0 IU/L | 5 RCPA | |
| Fractional Carboxyhemoglobin | WB | ±1% or 20% if > 5% | 5 RCPA | |
| Fractional Methemoglobin | WB | ±2% or 10% if > 20% | 5 RCPA | |
| Fractional Oxyhemoglobin | WB | ±3% or 4% if > 75% | 5 RCPA | |
| Fructosamine | Serum | ±15 umol/L or 6% if > 250 umol/L | 5 RCPA | |
| Fructosamine | Serum | ±2SD or 0.2 mmol/L (greater) | 6 API | |
| Gamma glutamyl transferase (GGT) | Serum | ±15% or 5 U/L (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Gamma glutamyl transferase (GGT) | Serum | ±2 SD or 15% (greater) | 4 AAB | |
| Gamma glutamyl transferase (GGT) | Serum | ±5 U/L or 12% if > 40 U/L | 5 RCPA | |
| Gastrin | Serum | ±10 pmol/L or 10% if > 100 pmol/L | 5 RCPA | |
| Gentamicin | Serum | ±25% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Gentamicin | Serum | ±25% or 1.0 µg/mL (greater) | 4 AAB | |
| Gentamicin | Serum | ±0.2 mg/L or 10% if > 2.0 mg/L | 5 RCPA | |
| Glucose | Serum | ±8% or 6 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Glucose | Body Fluids, CSF, Urine | ±10% | 2 WSLH | |
| Glucose | WB | ±20% or 15 mg/dL | 2 WSLH | |
| Glucose | Serum | ±6 mg/dL or 10% (greater) | 4 AAB | |
| Glucose | WB | ±6 mg/dL or 20% (greater) | 4 AAB | |
| Glucose | Serum, Body Fluids | ±0.4 mmol/L or 8% if > 5.0 mmol/L | 5 RCPA | |
| Glucose | CSF | ±0.2 mmol/L or 10% if > 2.0 mmol/L | 5 RCPA | |
| Glucose | Urine | ±1.0 mmol/L or 10% if > 10.0 mmol/L | 5 RCPA | |
| Glucose | CSF, Body Fluids | ±6 mg/dL or 10% (greater) | 6 API | |
| Glucose | WB | Waived | + 10 mg/dL or + 20% (greater) | 6 API |
| Glucose-6-phosphate-1-dehydrogenase (G6PD) | WB | ±3.0 U/g Hb or 30% if > 10 U/g Hb | 5 RCPA | |
| Growth Hormone | Serum | ±1.0 mU/L or 15% if > 7.0 mU/L | 5 RCPA | |
| Growth Hormone | Serum | ±3SD or ±0.2 ng/mL (greater) | 6 API | |
| Haptoglobin | Serum | ±0.1 g/L or 10% if > 0.8 g/L | 5 RCPA | |
| Hematocrit | WB | ±4% | 1 CLIA, 2 WSLH, 6 API | |
| Hematocrit | WB | ±6 mg/dL or 20% (greater) | 4 AAB | |
| Hematocrit | WB | ±4% or 20% if > 20% | 5 RCPA | |
| Hemoglobin | WB | ±4% | 1 CLIA, 2 WSLH, 6 API | |
| Hemoglobin | WB | ±7% | 4 AAB | |
| Hemoglobin | WB | ±5 g/L or 5% if > 100 g/L | 5 RCPA | |
| Hemoglobin A1c (Glycohemoglobin) | WB | ±8% | 1 CLIA, 2 WSLH, 6 API | |
| Hemoglobin A1c (Glycohemoglobin) | WB | ±5% | 4 AAB | |
| Hemoglobin A1c (Glycohemoglobin) | WB | IFCC | ±4 mmol/mol or 8% if > 45 mmol/mol | 5 RCPA |
| Hemoglobin A1c (Glycohemoglobin) | WB | NGSP | ±0.4% or 6% if > 6.7% | 5 RCPA |
| Hemoglobin, A2 | WB | ±0.3% or 10% if > 2.0 | 5 RCPA | |
| Hemoglobin, F | WB | ±0.5% or 30% if > 1.5% | 5 RCPA | |
| Hemoglobin, F | WB | ±2 SD or ±0.6% units (%) (greater) | 6 API | |
| Hemoglobin, Variant | WB | ±4% or 20% if > 20.0% | 5 RCPA | |
| Hemolysis, Serum Index | Serum | ±8 mg/dL or 10% if > 80 mg/dL | 5 RCPA | |
| Hepatitis (Anti-HBc, HBsAg, HBeAg, Anti-HCV) | Serum | Reactive (positive) or nonreactive (negative) | 1 CLIA, 2 WSLH | |
| Hepatitis, Surface Antibody (Anti-HBs) | Serum | Reactive (positive) or nonreactive (negative) | 1 CLIA, 2 WSLH | |
| Homocysteine | Serum | ±30% | 4 AAB | |
| Homocysteine | Serum | ±1.5 umol/L or 10% if > 15 umol/L | 5 RCPA | |
| Homovanillic Acid (HVA) | Urine | ±6 umol/L or 15% if > 40 umol/L | 5 RCPA | |
| Human Chorionic Gonadotropin (HCG) | Serum | ±18% or 3 mIU/mL (greater) or positive or negative | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Human Chorionic Gonadotropin (HCG) | Serum | ±18% or 2 SD (greater) | 4 AAB | |
| Human Chorionic Gonadotropin (HCG) | Serum | ±1.0 IU/L or 10% if > 10.0 IU/L | 5 RCPA | |
| Human Chorionic Gonadotropin (HCG) | Urine | ±5.0 IU/L or 10% if > 50 IU/L | 5 RCPA | |
| Hydroxyitraconazole | Serum | ±0.2 mg/L or 10% if > 2.0 mg/L | 5 RCPA | |
| Icterus, Serum Index | Serum | ±6.0 umol/L or 25% if > 25.0 umol/L | 5 RCPA | |
| IgA | Serum | ±20% | 1 CLIA, 6 API | |
| IgA | Serum | ±0.06 g/L or 10% if > 0.6 g/L | 5 RCPA | |
| IgD | Serum | ±0.2 g/L or 20% if > 1.0 g/L | 5 RCPA | |
| IgE | Serum | ±20% | 1 CLIA, 6 API | |
| IgE | Serum | ±20 kU/L or 20% if > 100 kU/L | 5 RCPA | |
| IgG | Serum | ±20% | 1 CLIA, 6 API | |
| IgG | Serum | ±25% | 4 AAB | |
| IgG | Serum | ±0.6 g/L or 10% if > 6 g/L | 5 RCPA | |
| IgG | CSF | ±0.02 g/L or 20% if > 0.1 g/L | 5 RCPA | |
| IgM | Serum | ±20% | 1 CLIA, 6 API | |
| IgM | Serum | ±0.08 g/L or 15% If > 0.5 g/L | 5 RCPA | |
| Immature granulocytes (IG's) | WB | ±3% or 30% if > 10% | 5 RCPA | |
| Infectious mononucleosis | Serum | ±2 dilutions or positive or negative | 1 CLIA, 2 WSLH | |
| INR | Plasma | ±15% | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| INR | Plasma | ±0.3 ratio or 15% if > 2.0 ratio | 5 RCPA | |
| Insulin | Serum | ±6 mU/L or 12% if > 5 mU/L | 5 RCPA | |
| Insulin-like Growth Factor (IGF-1) | Serum | ±3 nmol/L or 12% if > 25 nmol/L | 5 RCPA | |
| Insulin-like Growth Factor (IGF-1) | Serum | ±3 SD or ±0.2 ng/mL (greater) | 6 API | |
| Insulin-like Growth Factor Binding Protein (IGFBP-3) | Serum | ±15 nmol/L or 15% if > 100 nmol/L | 5 RCPA | |
| Iodine | Urine | ±80 nmol/L or 10% if > 800 nmol/L | 5 RCPA | |
| Iron (Fe) | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Iron (Fe) | Serum | ±20% | 4 AAB | |
| Iron (Fe) | Serum, Urine | ±3.0 umol/L or 12% if > 25.0 umol/L | 5 RCPA | |
| Iron Binding Capacity, Total (IBC) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Iron Binding Capacity, Total (IBC) | Serum, Urine | ±20% | 4 AAB | |
| Iron Binding Capacity, Total (IBC) | Serum | ±4 umol/L or 8% if > 50.0 umol/L | 5 RCPA | |
| Iron Binding Capacity, Unsaturated (UIBC) | Serum | ±20% | 2 WSLH | |
| Isopropanol | WB | ±25% | 6 API | |
| Itraconazole | Serum | ±0.1 mg/L or 10% if > 1.0 mg/L | 5 RCPA | |
| Lactate | Serum | ±0.2 mmol/L | 2 WSLH | |
| Lactate | CSF | ±10% | 2 WSLH | |
| Lactate | Serum | ±0.4 mmol/L or 3 SD (greater) | 3 CAP, 4 AAB, 6 API | |
| Lactate | Serum | ±0.5 mmol/L or 12% if > 4.0 mmol/L | 5 RCPA | |
| Lactate | CSF | ±0.3 mmol/L or 10% if > 3.0 mmol/L | 5 RCPA | |
| Lactate | Body Fluids | ±1.0 mmol/L or 25% if > 4.0 mmol/L | 5 RCPA | |
| Lactate | CSF | ±0.4 mmol/L or 3 SD (greater) | 6 API | |
| Lactate Dehydrogenase (LD, LDH) | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Lactate Dehydrogenase (LD, LDH) | Body Fluids | ±20% | 2 WSLH, 6 API | |
| Lactate Dehydrogenase (LD, LDH) | Serum | ±20% | 4 AAB | |
| Lactate Dehydrogenase (LD, LDH) | Serum, Body Fluids | ±20 U/L or 8% if > 250 U/L | 5 RCPA | |
| Lamellar Body Count | Amniotic Fluid | ±25% | 6 API | |
| Lead (Pb) | WB | ±10% or 2 µg/dL (greater) | 1 CLIA, 2 WSLH, 6 API | |
| Lead (Pb) | WB | ±4 µg/dL or 10% (greater) | 4 AAB | |
| Lead (Pb) | Urine | ±50 nmol/L or 10% if > 500 nmol/L | 5 RCPA | |
| Lead (Pb) | WB | ±0.05 umol/L or 10% if > 0.50 umol/L | 5 RCPA | |
| Lidocaine | Serum | ±3 SD or 10% (greater) | 3 CAP, 6 API | |
| Lipase | Serum | ±30% | 2 WSLH, 3 CAP, 4 AAB | |
| Lipase | Serum | ±12 U/L or 20% if > 60 U/L | 5 RCPA | |
| Lipase | Serum, Body Fluids | ±2 SD or ±30 U/L (greater) | 6 API | |
| Lipase | Body Fluids | ±24 U/L or 40% if > 60 U/L | 5 RCPA | |
| Lipemia, Serum Index | Serum | ±26 mg/dL or 10% if > 263 mg/dL | 5 RCPA | |
| Lipoprotein (a) | Serum | ±0.06 g/L or 20% if > 0.3 g/L | 5 RCPA | |
| Lithium | Serum | ±15% or 0.3 mmol/L (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Lithium | Serum | ±0.3 mmol/L or 20% (greater) | 4 AAB | |
| Lithium | Serum | ±0.2 mmol/L or 10% if > 2.0 mmol/L | 5 RCPA | |
| Luteinizing Hormone (LH) | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Luteinizing Hormone (LH) | Serum | ±1.5 IU/L or 15% if > 10.0 IU/L | 5 RCPA | |
| Lymphocytes, count | WB | ±2% or 20% if > 10% | 5 RCPA | |
| Magnesium | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Magnesium | Urine | ±25% | 2 WSLH | |
| Magnesium | Serum | ±25% | 4 AAB | |
| Magnesium | Serum, WB | ±0.1 mmol/L or 8% if > 1.25 mmol/L | 5 RCPA | |
| Magnesium | Urine | ±0.3 mmol/L or 15% if > 2.0 mmol/L | 5 RCPA | |
| Magnesium | Urine | ±0.1 mmol/L or 8% if > 1.25 mmol/L | 5 RCPA | |
| Magnesium | Urine | ±25% | 6 API | |
| Manganese | Serum | ±0.1 nmol/L or 8% if | 5 RCPA | |
| Manganese | Urine | ±3 nmol/L or 12% if > 25 nmol/L | 5 RCPA | |
| Manganese | WB | ±30 nmol/L or 12% if > 250 nmol/L | 5 RCPA | |
| Mean corpuscular hemoglobin (MCH) | WB | ±2 pg or 10% if > 20 pg | 5 RCPA | |
| Mean corpuscular hemoglobin concentration (MCHC) | WB | ±30 g/L or 10% if > than 300 g/L | 5 RCPA | |
| Mean corpuscular volume (MCV) | WB | ±5 fL or 10% if > 50 fL | 5 RCPA | |
| Mean platelet volume (MPV) | WB | ±2 fL or 20% if > 10 fL | 5 RCPA | |
| Metanephrine | Plasma | ±75 pmol/L or 15% if > 500 pmol/L | 5 RCPA | |
| Metanephrine | Urine | ±0.2 umol/L or 20% if > 1.0 umol/L | 5 RCPA | |
| Metanephrine, Free | Urine | ±30 nmol/L or 30% if > 100 nmol/L | 5 RCPA | |
| Methanol | Serum, Urine | ±25% | 6 API | |
| Methemoglobin | WB | ±0.003 | 2 WSLH | |
| Methemoglobin | WB | ±2 units (%) | 6 API | |
| Methotrexate | Serum | ±3 SD or 10% (greater) | 3 CAP, 6 API | |
| Methotrexate | Serum | ±0.10 ug/L or 10% if > 1.00 umol/L | 5 RCPA | |
| Methyoxytyramine | Plasma | ±36 pmol/L or 30% if > 120 pmol/L | 5 RCPA | |
| Mercury | Serum | ±30% or 3 ug/L | 2 WSLH | |
| Mercury | Serum, Urine, WB | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
| Microalbumin | Urine | ±10% | 2 WSLH | |
| Microalbumin | Urine | ±30% | 4 AAB | |
| Microalbumin | Urine | ±3 SD or ±30% (greater) | 6 API | |
| Monocytes, count | WB | ±3% or 30% if > 10% | 5 RCPA | |
| Mycophenolate | Serum | ±0.10 ug/L or 10% if > 1.00 mg/L | 5 RCPA | |
| Myoglobin | Serum | ±2 SD or 30% (greater) | 4 AAB | |
| Myoglobin | Serum | ±2 SD or ±15 ng/mL (greater) | 6 API | |
| N-Acetylprocainamide (NAPA) | Serum | ±25% | 3 CAP | |
| Neuron-specific enolase (NSE) | Serum | ±2 ug/L or 10% if > 20 ug/L | 5 RCPA | |
| Neutrophil, count | WB | automated | ±1% or 10% if > 10.0% | 5 RCPA |
| Nickel | Urine | ±40 nmol/L or 10% if > 400 nmol/L | 5 RCPA | |
| Noradrenaline | Urine | ±75 nmol/L or 15% if > 500 nmol/L | 5 RCPA | |
| Normetanephrine | Plasma | ±200 pmol/L or 20% if > 1000 pmol/L | 5 RCPA | |
| Normetanephrine | Urine | ±0.4 umol/L or 20% if > 2.0 umol/L | 5 RCPA | |
| Normetanephrine, Free | Urine | ±40 nmol/L or 20% if > 200 nmol/L | 5 RCPA | |
| Nortriptyline | Serum | ±3.0 ug/L or 10% if > 26.0 ug/L | 5 RCPA | |
| N-Telopeptides | Urine | ±80 nmolBCE/L or 10% if > 700 nmolBCE/L | 5 RCPA | |
| O2 Saturation (measured) | WB | ±3 SD or ±3 units (%) (greater) | 6 API | |
| Osmolality | Urine | ±10% | 2 WSLH | |
| Osmolality | Serum, Body Fluids | ±8 mmol/kg or 3% if > 266 mmol/kg | 5 RCPA | |
| Osmolality | Urine | ±6 mmol/kg or 2% if > 300 mmol/kg | 5 RCPA | |
| Oxidants | Urine | ±2SD or ±30 ug/mL (greater) PAP + | 6 API | |
| Oxyhemaglobin | WB | ±3SD or ±3 units (%) (greater) PAP + | 6 API | |
| Pancreatic Amylase | Serum | ±30% | 3 CAP | |
| Parathyroid hormone (PTH) | Serum | ±30% | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| Parathyroid Hormone (PTH) | Serum | ±1.0 pmol/L or 12% if > 8.0 pmol/L | 5 RCPA | |
| Partial thromboplastin time (PTT), (aPTT) | Plasma | ±15% | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| Partial thromboplastin time (PTT), (aPTT) | Plasma | ±10 sec or 25% if > 40 sec | 5 RCPA | |
| pCO2 | WB | ±8% or 5 mmHg (greater) | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| pCO2 | WB | ±2 mm Hg or 6% if > 34.0 mm Hg | 5 RCPA | |
| pH | WB | ±0.04 | 1 CLIA, 2 WSLH, 4 AAB, 5 RCPA, 6 API | |
| pH | Body Fluids | ±0.5 | 2 WSLH | |
| pH | Body Fluids | ±0.02 | 5 RCPA | |
| Phenobarbital | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Phenobarbital | Serum | ±20% | 4 AAB | |
| Phenobarbitone | Serum | ±0.7 mg/L or 10% if > 7.0 mg/L | 5 RCPA | |
| Phenytoin | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Phenytoin | Serum | ±25% | 4 AAB | |
| Phenytoin | Serum | ±0.8 mg/L or 10% if > 7.6 mg/L | 5 RCPA | |
| Phenytoin, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Phosphate | Serum | ±0.06 mmol/L or 8% if > 0.75 mmol/L | 5 RCPA | |
| Phosphate | Urine | ±3 mmol/L or 15% if > 20 mmol/L | 5 RCPA | |
| Phosphorus | Serum | ±10% or 0.3 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Phosphorus | Urine | ±15% or 0.5 mg/dL | 2 WSLH | |
| Platelet count | WB | ±25% | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Platelet count | WB | ±25x109/L or 25% If > 100x109/L | 5 RCPA | |
| pO2 | WB | ±15% or 15 mmHg (greater) | 1 CLIA, 2 WSLH, 6 API | |
| pO2 | WB | ±5 mm Hg or 6% if > 83 mm Hg | 5 RCPA | |
| Porphobilinogen | Urine | ±5 umol/L or 25% if > 20 umol/L | 5 RCPA | |
| Porphyrin, Total | Plasma | ±4 nmol/L or 20% if > 20 nmol/L | 5 RCPA | |
| Porphyrin, Total | Urine | ±60 nmol/ or 20% if > 300 nmol/L | 5 RCPA | |
| Porphyrin, Total | Fecal | ±40 umol/kg or 20% if > 200 umol/kg | 5 RCPA | |
| Porphyrin, Total RBC | WB | ±0.4 umol/Lrc or 20% if > 2.0 umol/Lrc | 5 RCPA | |
| Posaconazole | Serum | ±0.1 mg/L or 10% if > 1.0 mg/L | 5 RCPA | |
| Potassium (K) | Serum | ±0.3 mmol/L | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Potassium (K) | Urine | ±10% | 2 WSLH | |
| Potassium (K) | Serum | ±0.5 mmol/L | 4 AAB | |
| Potassium (K) | Serum | ±0.2 mmol/L or 5% if > 4.0 mmol/L | 5 RCPA | |
| Potassium (K) | Body Fluids | ±0.4 mmol/L or 10% if > 4 mmol/L | 5 RCPA | |
| Potassium (K) | Urine | ±2 mmol/L or 10% > 20 mmol/L | 5 RCPA | |
| Potassium (K) | Body Fluids | ±0.5 mmol/L | 6 API | |
| Prealbumin | Serum | ±5.0 mg/dL or 25% (greater) | 3 CAP, 6 API | |
| Prealbumin | Serum | ±25% | 4 AAB | |
| Prealbumin | Serum | ±0.04 g/L or 20% if > 0.2 g/L | 5 RCPA | |
| Primidone | Serum | ±25% | 3 CAP | |
| Pro B-natriuretic Peptide (proBNP) | Serum | ±30% | 1 CLIA | |
| Procainamide | Serum | ±25% | 3 CAP | |
| Procalcitonin | Serum | ±0.05 ng/mL or 30% if > 0.15 ng/mL | 5 RCPA | |
| Progesterone | Serum | ±25% | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| Progesterone | Serum | ±2 nmol/L or 15% if > 10 nmol/L | 5 RCPA | |
| Prolactin | Serum | ±20% | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| Prolactin | Serum | ±40 mIU/L or 10% if > 400 mIU/L | 5 RCPA | |
| Prostate Specific Antigen (PSA) | Serum | ±20% or 0.2 ng/mL (greater) | 1 CLIA, 2 WSLH, 6 API | |
| Prostate Specific Antigen (PSA) | Serum | ±0.9 ng/mL or 30% | 4 AAB | |
| Prostate Specific Antigen (PSA) | Serum, Urine | ±0.4 ug/L or 8% if > 5.0 ug/L | 5 RCPA | |
| Prostate Specific Antigen (PSA), Free | Serum | ±30% or 0.9 ng/mL | 2 WSLH | |
| Prostate Specific Antigen (PSA), Free | Serum | ±0.9 ng/mL or 30% | 4 AAB | |
| Prostate Specific Antigen (PSA), Free | Serum | ±0.2 ug/L or 15% if > 1.4 ug/L | 5 RCPA | |
| Prostate Specific Antigen (PSA), Free | Serum | ±3 SD or ±0.4 ng/mL (greater) | 6 API | |
| Prostatic Acid Phosphatase (PAP) | Serum | ±2 SD or ±30% (greater) | 6 API | |
| Protein, Total | Serum | ±8% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Protein, Total | Body Fluids, CSF, Urine | ±10% | 2 WSLH | |
| Protein, Total | Serum | ±10% | 4 AAB | |
| Protein, Total | Urine | ±44% | 4 AAB | |
| Protein, Total | Serum, Body Fluids | ±3.0 g/L or 5% if > 60 g/L | 5 RCPA | |
| Protein, Total | CSF | ±0.05 g/L or 10% if > 0.5 g/L | 5 RCPA | |
| Protein, Total | CSF, Body Fluids | ±3.0 SD or ±10% (greater) | 6 API | |
| Protein, Total | Urine | ±0.1 g/L or 10% if > 1.00 g/L | 5 RCPA | |
| Protein C, Functional | Plasma | ±12% or 20% if > 60% | 5 RCPA | |
| Protein S, Free Antigen | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
| Protein S, Free Functional | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
| Protein S, Total Antigen | Plasma | ±10% or 25% if > 40% | 5 RCPA | |
| Prothrombin Time (PT) | Serum | ±15% | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| Prothrombin Time (PT) | Plasma | ±2.0 sec or 20% if > 10 sec | 5 RCPA | |
| Quinidine | Serum | ±25% | 3 CAP | |
| RBC, Red Cell count, Erythrocyte Count | WB | automated differential | ±4% | 1 CLIA, 2 WSLH, 6 API |
| RBC, Red Cell count, Erythrocyte Count | WB | quantitative | ±6% | 4 AAB |
| Red Cell Distribution Width (RDW) | WB | ±2% or 20% if > 10% | 5 RCPA | |
| Reticulocyte count | WB | ±30% or 2 SD (greater) | 4 AAB | |
| Reticulocyte count | WB | automated % | ±1.0% or 10% if > 10% | 5 RCPA |
| Reticulocyte count | WB | automated absolute | ±10x109/L or 10% if > 100x109/L | 5 RCPA |
| Reticulocyte count | WB | manual % | ±0.6% or 30% if > 2% | 5 RCPA |
| Reticulocyte count | WB | manual absolute | ±21x109/L or 30% if > 70x109/L | 5 RCPA |
| Rheumatoid Factor (RF) | Serum | ±2 dilutions or positive or negative | 1 CLIA, 2 WSLH | |
| Rheumatoid Factor (RF) | Serum | ±12 IU/mL or 20% if > 60 IU/mL | 5 RCPA | |
| Rheumatoid Factor (RF) | Serum | ±20 IU/mL or ±3SD | 6 API | |
| Rubella | Serum | ±2 dilutions or positive or negative or immune or nonimmune | 1 CLIA, 2 WSLH | |
| Rubella | Serum | ±10 IU/mL or ±3SD | 6 API | |
| Salicylates | Serum | ±15% or 2 µg/mL or 0.2 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Salicylates | Serum | ±25% | 4 AAB | |
| Salicylates | Serum | ±14 mg/L or 10% if > 143.0 mg/L | 5 RCPA | |
| Selenium | Serum | ±0.18 umol/L or 12% if > 1.50 umol/L | 5 RCPA | |
| Selenium | Urine | ±0.06 umol/L or 12% if > 0.50 umol/L | 5 RCPA | |
| Selenium | WB | ±0.3 umol/L or 12% if > 2.50 umol/L | 5 RCPA | |
| Serotonin | Urine | ±0.2 umol/L or 20% if > 1.0 umol/L | 5 RCPA | |
| Sex hormone binding globulin (SHBG) | Serum | ±6 nmol/L or 12% if > 50 nmol/L | 5 RCPA | |
| Sirolimus | Serum | ±0.5 ug/L or 10% if > 5.0 ug/L | 5 RCPA | |
| Sodium (Na) | Serum | ±4 mmol/L | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Sodium (Na) | Urine | ±10% or 4 mmol/L | 2 WSLH | |
| Sodium (Na) | Serum | ±3 mmol/L or 2% if > 150 mmol/L | 5 RCPA | |
| Sodium (Na) | Body Fluids | ±6 mmol/L or 4% if > 150 mmol/L | 5 RCPA | |
| Sodium (Na) | Urine | ±4 mmol/L or 10% if > 40 mmol/L | 5 RCPA | |
| Sodium (Na) | Body Fluids | ±4 mmol/L | 6 API | |
| Specific Gravity | Urine | ±0.010 | 2 WSLH, 4 AAB, 6 API | |
| T3 Free, (FT3) Triiodothyronine, Free | Serum | ±0.7 pmol/L or 20% if > 3.5 pmol/L | 5 RCPA | |
| T3, Total Triiodothyronine | Serum | ±30% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| T3, Total Triiodothyronine | Serum | ±0.2 nmol/L or 15% if > 1.3 nmol/L | 5 RCPA | |
| T3 Uptake | Serum | ±18% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| T4, Thyroxine | Serum | ±20% or 1.0 µg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| T4, Thyroxine | Serum | ±12 nmol/L or 10% if > 120 nmol/L | 5 RCPA | |
| T4, Free Thyroxine, (FT4) | Serum | ±15% or 0.3 ng/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| T4, Free Thyroxine, (FT4) | Serum | ±1.5 pmol/L or 12% if > 12.0 pmol/L | 5 RCPA | |
| Tacrolimus | Serum | ±0.5 ug/L or 10% if > 5.0 ug/L | 5 RCPA | |
| Testosterone | Serum | ±30% or 20 ng/dL or 0.2 ng/mL (greater) | 1 CLIA, 2 WSLH, 4 AAB, 6 API | |
| Testosterone | Serum | ±0.4 nmol/L or 15% if > 2.7 nmol/L | 5 RCPA | |
| Thallium | Serum, Urine | ±1 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
| Thallium | WB | ±2 nmol/L or 10% if > 10 nmol/L | 5 RCPA | |
| Theophylline | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Theophylline | Serum | ±25% | 4 AAB | |
| Theophylline | Serum | ±0.5 mg/L or 10% if > 5.4 mg/L | 5 RCPA | |
| Thrombin Time (TT) | Plasma | ±3.0 sec or 25% if > 12.0 sec | 5 RCPA | |
| Thyroglobulin | Serum | ±0.2 ug/L or 12% if > 1.7 ug/L | 5 RCPA | |
| Thyroglobulin | Serum | ±20 IU/mL or ±2SD | 6 API | |
| Thyroid Microsoml AB (Anti-TPO) | Serum | ±20 IU/mL or ±2SD | 6 API | |
| Thyroid Stimulating Hormone (TSH) | Serum | ±20% or 0.2 mIU/L (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Thyroid Stimulating Hormone (TSH) | Serum | ±0.1 mU/L or 20% if > 0.5 mU/L | 5 RCPA | |
| Tobramycin | Serum | ±20% | 1 CLIA, 3 CAP, 6 API | |
| Tobramycin | Serum | ±20% | 2 WSLH | |
| Tobramycin | Serum | ±0.2 mg/L or 10% if > 2.0 mg/L | 5 RCPA | |
| Transferrin | Serum | ±20% | 3 CAP | |
| Transferrin | Serum | ±10% | 4 AAB | |
| Transferrin | Serum | ±0.2 g/L or 8% if > 2.50 g/L | 5 RCPA | |
| Triglycerides | Serum | ±15% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Triglycerides | Body Fluids | ±25% | 2 WSLH | |
| Triglycerides | Serum | ±25% | 4 AAB | |
| Triglycerides | Serum | ±0.2 mmol/L or 12% if > 1.60 mmol/L | 5 RCPA | |
| Triglycerides | Body Fluids | ±0.3 mmol/L or 25% if > 1.2 mmol/L | 5 RCPA | |
| Triglycerides | Body Fluids | ±3.0 SD or ±10 mg/dL (greater) | 6 API | |
| Troponin I | Serum | ±30% or 0.9 ng/mL (greater) | 1 CLIA, 2 WSLH, 6 API | |
| Troponin I | Serum | ±30% | 4 AAB | |
| Troponin I | Serum | ±0.002 ug/L or 20% if > 0.010 ug/L | 5 RCPA | |
| Troponin I | Serum | POC | ±0.01 ug/L or 20% if > 0.05 ug/L | 5 RCPA |
| Troponin T | Serum | ±30% or 0.2 ng/mL (greater) | 1 CLIA, 2 WSLH, 6 API | |
| Troponin T | Serum | ±30% | 4 AAB | |
| Troponin T | Serum | ±0.001 ug/L or 20% if > 0.050 ug/L | 5 RCPA | |
| Troponin T | Serum | ±10 ng/L or 20% if > 50 ng/L | 5 RCPA | |
| Tryptase | Serum | ±0.6 ug/L or 15% if > 4.0 ug/L | 5 RCPA | |
| Urate | Serum | ±0.030 mmol/L or 8% if > 0.380 mmol/L | 5 RCPA | |
| Urate | Body Fluids | ±0.06 mmol/L or 16% if > 0.38 mmol/L | 5 RCPA | |
| Urate | Urine | ±0.3 mmol/L or 15% if > 2 mmol/L | 5 RCPA | |
| Urea Nitrogen (BUN) | Serum | ±9% or 2 mg/dL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 4 AAB, 6 API | |
| Urea Nitrogen (BUN) | Urine | ±10% | 2 WSLH | |
| Urea Nitrogen (BUN) | Serum | ±0.5 mmol/L or 12% if > 4.0 mmol/L | 5 RCPA | |
| Urea Nitrogen (BUN) | Body Fluids | ±1.0 mmol/L or 24% if > 4.0 mmol/L | 5 RCPA | |
| Urea Nitrogen (BUN) | Urine | ±20 mmol/L or 10% if > 200 mmol/L | 5 RCPA | |
| Urea Nitrogen (BUN) | Body Fluids | ±9% or 2 mg/dL (greater) | 6 API | |
| Uric Acid | Serum | ±10% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Uric Acid | Serum | ±17% | 4 AAB | |
| Uric Acid | Urine | ±17% or 2 mg/dL | 2 WSLH | |
| Uric Acid | Body Fluids | ±17% | 6 API | |
| Valproate | Serum | ±4.0 mg/L or 10% if > 36.0 mg/L | 5 RCPA | |
| Valproic Acid | Serum | ±20% | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Valproic Acid | Serum | ±25% | 4 AAB | |
| Valproic Acid, Free | Serum | ±3 SD or 10% (greater) | 3 CAP | |
| Vanadium | Serum | ±1 nmol/L or 10% if > 10nmol/L | 5 RCPA | |
| Vanadium | Urine | ±2 nmol/L or 10% if > 10nmol/L | 5 RCPA | |
| Vancomycin | Serum | ±15% or 2 µg/mL (greater) | 1 CLIA, 2 WSLH, 3 CAP, 6 API | |
| Vancomycin | Serum | ±25% or 1.0 ug/mL (greater) | 4 AAB | |
| Vancomycin | Serum | ±2.0 mg/L or 10% if > 20.3 mg/L | 5 RCPA | |
| Vitamin A | Serum | ±0.2 umol/L or 12% if > 1.7 umol/L | 5 RCPA | |
| Vitamin B1 | Serum | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
| Vitamin B2 | Serum | ±25 nmol/L or 10% if > 250 nmol/L | 5 RCPA | |
| Vitamin B6 | Plasma, WB | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
| Vitamin B12 | Serum | ±25% or 30 pg/mL (greater) | 1 CLIA, 2 WSLH, 6 API | |
| Vitamin B12 | Serum | ±25% | 4 AAB | |
| Vitamin B12 | Serum | ±18 pmol/L or 15% if > 120 pmol/L | 5 RCPA | |
| Vitamin C | Serum | ±7 umol/L or 20% if > 35 umol/L | 5 RCPA | |
| Vitamin D3 | Serum | ±9 nmol/L or 15% if > 60 nmol/L | 5 RCPA | |
| Vitamin E | Serum | ±3 umol/L or 12% if > 25 umol/L | 5 RCPA | |
| von Willebrand Activity | Plasma | ±4% or 40% if > 10% | 5 RCPA | |
| von Willebrand factor, Antigen (vWF:Ag) | Plasma | ±3% or 30% if > 10% | 5 RCPA | |
| von Willebrand Collagen binding (vWF:CB) | Plasma | ±4% or 40% if > 10% | 5 RCPA | |
| von Willebrand Ristocetin Cofactor (vWF:rCo) | Plasma | ±4% or 40% if > 10% | 5 RCPA | |
| Voriconazole | Serum | ±0.2 mg/L or 10% if > 2.0 mg/L | 5 RCPA | |
| WBC, White Cell Count, Leukocyte count) | WB | automated differential | ±10% | 1 CLIA, 2 WSLH, 6 API |
| WBC, White Cell Count, Leukocyte count) | WB | ±15% | 4 AAB | |
| WBC, White Cell Count, Leukocyte count) | WB | ±0.5x109/L or 10% if > 5.0 x109/L | 5 RCPA | |
| WBC Differential | WB | ±3SD based on the percentage of different types of white blood cells in the samples | 1 CLIA, 2 WSLH, 6 API | |
| WBC Differential | WB | automated differential | ±3% or 30% if > 10% | 5 RCPA |
| Zinc | Serum, Urine | ±2 umol/L or 10% if > 20.0 umol/L | 5 RCPA | |
| Zinc | WB | ±6 umol/L or 10% if > 60 umol/L | 5 RCPA |
Sources
TEa Sources
| Abbreviation | Source | Effective Date |
|---|---|---|
| 1 CLIA | CLIA – Federal Register | July 2024 |
| 2 WLSH | Wisconsin State Laboratory of Hygiene | January 2025 |
| 3 CAP | College of American Pathologists | January 2025 |
| 4 AAB | American Association of Bioanalysts | 2022 |
| 5 RCPA | The Royal College of Pathologists of Australasia and the Australasian Clinical Biochemist association Quality Assurance Program | December 2022 |
| 6 API | American Proficiency Institute | May 2025 |
